X

Drug Profile

Research programme: cell therapies - ViaCell

Latest Information Update: 06 Apr 2011

Price : $50 ^*

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator ViaCell
Developer Amgen; ViaCell
Class Cell therapies
Mechanism of Action Cell replacements

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No

Highest Development Phases

No development reported Amyotrophic lateral sclerosis; Heart failure; Muscular dystrophies; Stroke

Most Recent Events

08 Sep 2008 Preclinical development is ongoing in USA
09 Sep 2005 Preclinical data from a media release have been added to the Heart failure pharmacodynamics section
30 Mar 2005 Preclinical trials in Heart failure in USA (unspecified route)

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com